As soon as Marit finished his speech, everyone at the scene looked at each other, and then exploded.
People say all sorts of things, but no one can say there is anything wrong with Marit's remarks, because what he said is absolutely correct and naturally stands on the side of morality.
Indeed, if the drug is expensive and ordinary people can't afford it, how can we perform organ transplants? This will be a major constraint.
The key point is that Marit is standing from the perspective of all mankind and hopes that Pumpkin Vine Pharmaceuticals can transfer the relevant drug patents. This view is also in line with the political propositions of mainstream "white left" in Europe and the United States.
So immediately some foreign doctors started applauding. This applause was in support of Professor Marit. In other words, those who applauded supported the idea that patents should not be held by a few companies, but should be contributed.
Of course, it is unknown how many of them are genuine supporters and how many are agents arranged by Marit.
But at least in public, there are public calls to prevent patents from becoming a tool for a few companies to make profits, and this is definitely not something that can be easily refuted.
When Marit saw the reaction on the scene, he smiled slightly in his heart.
It's true that he is a professor, hospital director, and university vice president, but these identities are not enough. The key is how to convert identities into money.
The reason why Marit came uninvited was that he was eager to take the initiative in the two transplant operations, and he even went so far as to ask for the transfer of patents in the name of the International Society for Organ Transplantation.
All of this comes from the financial backer behind him, Johnson Company.
Johnson & Johnson is the second largest pharmaceutical company in the United States after Pfizer, and even Lilly Pharmaceuticals can only rank behind them.
Chen Xia had previously invented so many drugs for the digestive system, respiratory system, and endocrine system, but he only cooperated with Pfizer. This also led to Pfizer becoming increasingly dominant in the United States.
This is something that Johnson & Johnson and Lili Pharmaceuticals cannot tolerate, and they must find a way to stop it.
This is also the reason why Lilai Pharmaceutical ignored the patent protection law and wanted to forcibly imitate nebulized drugs.
Professor Marritt's performance today was actually instigated by Johnson & Johnson.
Every pharmaceutical company has its own flagship product. For example, Johnson & Johnson's medical devices have always ranked high and are also the "good friends" of many surgeons.
The promotion of organ transplantation also relies on the sponsorship of these pharmaceutical companies, and pharmaceutical companies also hope that doctors can perform as many surgeries as possible. In this way, more surgical equipment will be consumed, and the pharmaceutical companies’ sales and profits will be higher.
This is a natural interest group.
Dr. Marritt is not a white lotus. As a top expert in the field of surgery, he has close ties with Johnson Pharmaceuticals. To put it bluntly, he is just a pawn of capital.
This time, I heard that the Pumpkin Vine Pharmaceutical Company in Hong Kong has invented an anti-rejection drug and will conduct teaching operations and clinical trials in China.
Johnson Company immediately sent Professor Marit to participate in the teaching operation in an official capacity, and immediately took the initiative of the operation in the name of the association's chairman.
The same applies to this disease analysis meeting.
Then he publicly challenged the association at the meeting and bluntly demanded that the patent rights be taken back by the association.
This is a very good opportunity, even though this is not a formal, global, official organ transplantation academic conference.
But now, those sitting in the audience are almost all the surgeons who are engaged in organ transplantation in the world.
It's just that there are more doctors from Hua and Hong Kong. According to the previous levels, doctors from these two regions were not qualified to participate.
Now Yuezhou Hospital, or Chen Xia, is facing an embarrassing problem.
It would be fine if he agreed to Marit's request. Although he would suffer heavy financial losses, at least his reputation would be good, as he would be known as a selfless person.
But what if he refuses?
There is a rule in the international medical community that if you want to promote a new technology, new invention, new drug, or new surgical procedure, you must first obtain approval from the industry association.
This recognition represents the recognition of the international mainstream medical community, so that it can be commercialized and converted into profits.
Don’t underestimate the recognition of this association, as it is an important indicator of whether these new drugs can enter developed countries in Europe and the United States.
In Europe and the United States, the opinions of a professional association can indirectly represent official opinions.
Because politicians do not understand this professional knowledge, they need industry associations to judge what is good and bad, reasonable and unreasonable.
This gives these industry associations a lot of power. If you are recognized by the association, you are "mainstream"; if you are not recognized, you are "non-mainstream". It's that simple.
A month ago, Marit had clearly told Chen Xia that his attitude was very clear.
If everything goes well at this medical condition analysis meeting, a preliminary expert consensus can be formed immediately on the spot, and when the International Society for Organ Transplantation is officially convened in the second half of the year, it can become an official "recommended guideline".
But the prerequisite is that Chen Xia, or the Pumpkin Vine Company, must agree to the patent transfer request. If they do not agree, they will not be able to enter European and American countries.
Some readers might ask, isn't Pumpkin Vine a close partner in the United States, Pfizer? Could it be that even a large pharmaceutical company like Pfizer can't help these drugs get FDA approval?
I can't agree to it. Wherever there are people, there are bound to be factions. Pfizer is not omnipotent.
For example, Pfizer holds the largest share of digestive system drugs in the United States.
Then they will have enough motivation to bribe gastroenterologists and make them their pawns, thereby further controlling the American Society of Gastroenterology and even the International Society of Gastroenterology.
Chen Xia chose Pfizer because of this advantage. Omeprazole could successfully enter the American market, be successfully listed, and make money.
Pfizer was able to quickly influence another "American Endocrinology Society"
This was mainly due to Chen Xia's burning of "Lilai Pharmaceutical", which allowed Pfizer to rely on the patent of pumpkin vines to quickly occupy the market for diabetes drugs.
The good news that Pfizer Pharmaceuticals will build the world's largest diabetes production base in China has also led to the rapid bribery of most endocrinologists and metabolic doctors, thereby controlling relevant medical associations.
By the same token, Johnson's strength lies in medical equipment and they deal a lot with surgeons, so the "International Society for Organ Transplantation" is their stronghold and is secretly influenced by them.
Pfizer can influence some members of the association, but this is a minority. This is the game of capital, or it can be said that everyone has drawn the lines in advance.
It is precisely because of this background that Marit has great confidence in completing the instructions of his financial backers.
Chen Xia is the financial backer of Pumpkin Vine Pharmaceuticals. This can be hidden from most people, but it cannot be hidden from Johnson Corporation. They want to force Chen Xia to sign a humiliating treaty.
Of course, the final patent transfer fee will definitely satisfy Chen Xia. It is more than 10 million US dollars for a drug. After all, this is a sky-high price, and he will have to pay it back.
Continue read on readnovelmtl.com